cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Prothena Corporation Plc
4 own
7 watching
Current Price
$72.29
$0.28
(0.39%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
3,808.11M
52-Week High
52-Week High
79.65
52-Week Low
52-Week Low
21.06
Average Volume
Average Volume
0.49M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
43.4636
iconMarket Capitalization3,808.11M
icon52-Week High79.65
icon52-Week Low21.06
iconAverage Volume0.49M
iconDividend Yield--
iconP/E Ratio43.4636
What does the Prothena Corporation Plc do?
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. It is developing antibody-based product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002 that has completed Phase Ib clinical trial for treating Parkinson's disease and other related synucleinopathies; PRX003, a monoclonal antibody that is in Phase Ib for the treatment of psoriasis and other inflammatory diseases; and PRX004, a monoclonal antibody that is under preclinical development. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein. Prothena Corporation plc was incorporated in 2012 and is headquartered in Dun Laoghaire, Ireland.
Read More
How much money does Prothena Corporation Plc make?
News & Events about Prothena Corporation Plc.
Business Wire
2 months ago
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced new preclinical data from its PRX012 program, a potential best-in-class anti-amyloid beta (A) product...
Ticker Report
3 months ago
Prothena Co. plc (NASDAQ:PRTA Get Rating) Stock analysts at HC Wainwright upped their FY2025 earnings per share (EPS) estimates for Prothena in a research note issued to investors on Friday, February 24th. HC Wainwright analyst A. Fein now anticipates that the biotechnology company ...
Business Wire
5 months ago
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it priced an underwritten public offering of 3,250,000 of its ordinary shares at a price to the...
Business Wire
5 months ago
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today presented data from the completed phase 3 VITAL study demonstrating that in a post hoc analysis of patients with...
Business Wire
7 months ago
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will present survival data from the phase 3 VITAL study at an oral presentation at the...
Frequently Asked Questions
Frequently Asked Questions
What is Prothena Corporation Plc share price today?
plus_minus_icon
Can Indians buy Prothena Corporation Plc shares?
plus_minus_icon
How can I buy Prothena Corporation Plc shares from India?
plus_minus_icon
Can Fractional shares of Prothena Corporation Plc be purchased?
plus_minus_icon
What are the documents required to start investing in Prothena Corporation Plc stocks?
plus_minus_icon
What is today’s traded volume of Prothena Corporation Plc?
plus_minus_icon
What is today’s market capitalisation of Prothena Corporation Plc?
plus_minus_icon
What is the 52-Week High and Low Range of Prothena Corporation Plc?
plus_minus_icon
What percentage is Prothena Corporation Plc down from its 52-Week High?
plus_minus_icon
What percentage is Prothena Corporation Plc up from its 52-Week Low?
plus_minus_icon
Current Price
$72.29
$0.28
(0.39%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Ascendis Pharma A/S
Ascendis Pharma A/S
$90.40
$-1.82 (-1.97 %)
Blueprint Medicines Corp
Blueprint Medicines Corp
$60.03
$2.03 (3.50 %)
Catalent, Inc.
Catalent, Inc.
$39.96
$1.14 (2.94 %)
Sage Therapeutics Inc
Sage Therapeutics Inc
$56.53
$2.79 (5.19 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Ascendis Pharma A/S
Ascendis Pharma A/S
$90.40
$-1.82 (-1.97 %)
Blueprint Medicines Corp
Blueprint Medicines Corp
$60.03
$2.03 (3.50 %)
Catalent, Inc.
Catalent, Inc.
$39.96
$1.14 (2.94 %)
Sage Therapeutics Inc
Sage Therapeutics Inc
$56.53
$2.79 (5.19 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00